News

Managed care executives involved with Medicare Advantage products should consider the impact of product design and cost sharing on elderly consumers, according to the findings of a recent poll.

FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1.

Biopharmaceutical manufacturers’ at-risk day is coming. Here’s how to prepare.

Telemedicine is gaining broader acceptance, yet legal restrictions and reimbursement barriers continue to slow its momentum.

The reasons for recent jumps in generic drug prices are varied, but some common themes have emerged in a new study by National Center for Policy Analysis Senior Fellow Devon Herrick.

While expansion means better health, it is creating logistical and operational concerns that health plans must rapidly address.

Purchasers, manufacturers explore new pricing models

Further research may determine whether changing sedentary behavior will reduce long-term outcomes.

A novel influenza drug will advance in development, thanks to funding from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).

The FDA’s accelerated drug reviews skip some important research methods – they typically do not use trials with active comparators or clinical outcome measures, according to two new studies.

As hospitals prepare for the mandated management of episodes of care, they will threaten the value proposition of most managed care plans.

Health policy experts generally agree that properly tailored transparency tools can help to hold down prices. What is not settled at this point is what transparency should look like.

FDA approved Tresiba (insulin degludec injection, Novo Nordisk) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection, Novo Nordisk) for the treatment of diabetes mellitus.

FDA has approved cariprazine (Vraylar, Allergan and Gedeon Richter Plc.) for the treatment of schizophrenia and bipolar I disorder in adults.

Five initiatives, five success stories

Most managed care executives believe they will recoup their investments in population health management (PHM) within four years, but many don’t have a clear vision of the pathway to success

Those who are in decision-making roles must study how other countries address healthcare financing and delivery so as to bring the best initiatives of the studied country to the healthcare systems they oversee.

AstraZeneca recently released positive new data on its experimental non-small cell lung cancer (NSCLC) drug, AZD9291 (osimertinib)

Most payers and employers now offer high-deductible health plans (HDHPs), but questions remain regarding whether these options will actually help plans save on healthcare costs.

Questions remain regarding how those plans will impact hospital revenue.

FDA’s approval of Vertex Pharmaceutical’s groundbreaking lumacaftor/ivacaftor (Orkambi) for cystic fibrosis (CF) is the first drug to treat the underlying cause of CF in people ages 12 and older with two copies of the F508del mutation.

Proteus Digital Health along with the pharmaceutical company, Otsuka, has submitted the first Digital Medicine New Drug Application (NDA) for the combination tablet of Abilify (aripiprazole) embedded with a Proteus ingestible sensor.

Aspirin should be taken daily in low doses by certain people to not only prevent heart disease and stroke, but also colon cancer, according to new draft guidelines.

If a crisis were to suddenly arise for your organization, would your people be ready to handle it?

While the introduction of the Health Insurance Marketplace plans in 2014 has accelerated the trend of more Americans with HDHPs, the number of such plans was already increasing before then.

Blue Cross Blue Shield of Michigan (BCBSM) is collaborating with the University of Michigan Health System, physician organizations and pharmacists across the state to team up pharmacists with patient care teams as part of a new initiative to help patients manage and comply with their medication plans.

A deeper dive into the proposed payer mergers reveals how they could impact market dynamics.

The latest specialty drug pricing debate centers around Daraprim for toxoplasmosis infections, the price of which skyrocketed 5,000% within a month.